[Skip to Navigation]
Sign In
November 2015

Value of the 340B Drug Discount Program

Author Affiliations
  • 1Leukemia Department, MD Anderson Cancer Center, Houston, Texas
  • 2Division of Hematology and Medical Oncology, Josephine Ford Cancer Institute, Detroit, Michigan
JAMA Oncol. 2015;1(8):1029-1030. doi:10.1001/jamaoncol.2015.2168
Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    340B Pricing Has Not Realized Its Promise
    Ian Schnadig, MD | Compass Oncology, US Oncology Research
    Dear Sir/Madam:

    Dr. Kantarjian's article, \"The Value of 340B Pricing\" woefully misses the point of the costs of delivery of care in a hospital-based environment.

    One-third of US hospitals purchase chemotherapy drugs through the 340B program, which discounts drugs up to 50%. Community cancer clinics are not eligible for these same discounts. Notwithstanding these steep discounts, the costs of care in the hospital setting remain steeply higher. Researchers at the Berkeley Research Group examined the expanded delivery of oncology services by 340B hospitals through the acquisition of community cancer practices, which they concluded leads to higher costs to the Medicare

    The cost of treating cancer patients is significantly lower to both patients and the Medicare program when care is delivered in community cancer clinics as opposed to the outpatient hospital setting. According to recent data, total Medicare spending on patients receiving chemotherapy in the community clinic is 14.2% lower than the hospital outpatient department, which equals $623 million per year.(1)

    The cost of providing the same cancer care in a hospital outpatient department (HOPD) is significantly higher than the same care delivered at a community cancer clinic: 126% higher costs for administering common cancer drugs and 100% higher costs for drug infusion services overall. Patient co-payments are approximately 10% lower in the clinic, equaling more than $650 in savings for each Medicare beneficiary fighting cancer per year.

    Additionally, the average out-of-pocket patient cost for commonly used cancer drugs is $134 less per dose if received in an oncologist’s office. (1)

    Data show between 2009 and 2012, Medicare beneficiaries paid $4.05 million more
    in out-of-pocket costs because of the higher patient co-payment due to the HOPD for the exact same chemotherapy services performed at community cancer practices.(2)

    The 340B program, despite its promise, has led to higher chemotherapy reimbursement for hospitals. A new IMS Institute report finds that more Americans are receiving cancer care
    from oncologists, whose practices have been bought by hospitals, thereby
    increasing costs. Compounding this trend, reimbursement levels for drug administration costs in HOPD are, on average, 189 percent higher than physician office reimbursement costs.(3)

    This was an unusual article for JAMA to publish and creates an appearance of bias in favor of the hospital systems whose lobbying organization provided editorial support for the work. We hope that appropriate citations will be provided for this article in a forthcoming issue.

    (1) Cost Differences in Cancer Across Settings, The Moran Company, August 2013
    (2) Berkeley Research Group, \"Impact on Medicare Payments of Shift in Site of Care for Chemotherapy Administration\", June 2014
    (3) IMS Institute for Healthcare Informatics, \"Innovation in Cancer Cancer and Implications for Health Systems: Global Oncology Trend Report,\" May 2014

    Sincerely yours,

    Ian Schnadig, MD
    Chair, Pharmacy & Therapeutics
    GU Chair, Pathways Task Force